Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vitro STAT3 phosphorylation inhibition study in psoriasis, Crohn's disease, and SLE blood samples
NL-OMON35388Active, not recruiting
- Sponsor
- TNO
- Start
- Oct 2011
- Countries
- 1
01
Overview
Open-label trial in plaque psoriasis, Crohn's disease and systemic lupus erythematosus (SLE) (3 cohorts), sponsored by TNO. Primary endpoints: STAT3 phosphorylation measurement, Inhibition of STAT3 phosphorylation by test compounds and 1 more. Started Oct 2011; status: active, not recruiting.
02
Conditions
plaque psoriasisCrohn's diseasesystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON35388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35388.